Abcl stock forecast.

6.7900. 6.7900. 2,102,000. *Close price adjusted for splits. **Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data... Discover historical prices for ABCL stock on Yahoo Finance. View daily, weekly or monthly format back to when AbCellera Biologics Inc. stock was issued.AbCellera Biologics ( ABCL) started trading on the Nasdaq on December 11 last year. The issue price was $20, above the originally stated $14-17 range but based on the first day’s trading, still ...Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media ABCL vs. SMMT, MRUS, RYZB, ARVN, IRON, AMRX, MRVI, MIRM, PCRX, and PNTFor Abcam plc stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Abcam plc stock forecast of 1878.0, a high forecast of 2240.87, and a low forecast of 1688.28. The average Abcam plc stock forecast 2026 represents a 53.18% increase from the last price of 1226.0.Dec 1, 2023 · Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Based on 1 Wall Street analysts offering 12 month price targets for Orasure Technologies in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 6.57% change from the last price of $5.63. Highest Price Target $6.00. Average Price Target $6.00.

805.37p. (31.55% Upside) Based on 13 Wall Street analysts offering 12 month price targets for HSBC Holdings in the last 3 months. The average price target is 805.37p with a high forecast of 1,000.00p and a low forecast of 575.00p. The average price target represents a 31.55% change from the last price of 612.20p. Highest Price Target 1,000.00p.

Abcellera Biologics earnings beat by $0.11, revenue fell short of estimates. By Investing.com. • Aug 03, 2023. Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of ...Get in Touch. Micron Technology Inc., the largest US maker of computer memory semiconductors, suffered its worst stock decline in two months after warning …805.37p. (31.55% Upside) Based on 13 Wall Street analysts offering 12 month price targets for HSBC Holdings in the last 3 months. The average price target is 805.37p with a high forecast of 1,000.00p and a low forecast of 575.00p. The average price target represents a 31.55% change from the last price of 612.20p. Highest Price Target 1,000.00p.Nov 2, 2023 · AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.

ABCL. The Nasdaq Stock Market. Indicate by check mark whether the registrant (1) ... The market price of our common stock could decline if one or more of these ...

Where is Abcam stock heading? Wall Street analysts weigh in with their latest ratings and ABC price targets at PriceTargets.com. Skip to main content. Ratings Issuers. ... The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of ...

Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...5 abr 2023 ... Their average price target stands at $19, implying 266% upside potential. AbCellera Biologics (ABCL). Pipette adding fluid to one of several ...Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL. Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...JYNT. The Joint Corp. 9.24. -0.01. -0.11%. In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap ...

AbCellera Biologics Stock Chart and Share Price Forecast, Short-Term "ABCL" Stock Prediction for Next Days and Weeks Walletinvestor.com AbCellera Biologics Inc (ABCL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...On September 12, 2023, Veronique Lecault, the COO of AbCellera Biologics Inc (NASDAQ:ABCL), made a significant purchase of 20,000 shares of the company's stock.Sep 25, 2023 · AbCellera's Q2 2023 financials reveal declining revenues and high R&D expenses, leading to caution in investment decision. Learn why I rate ABCL stock a hold. Value a Constant Growth Stock Financial analysts forecast Best Buy Company (BBY) growth for the future to be 13 percent. Their recent dividend was $0.49. What is the value of their stock when the required rate of return is 14.13 percent? $3.92 $4.90 $43.36 $49.00. $49. About us. About Quizlet; How Quizlet works; Careers;

Now, shares are making a pullback to their 21-day line, creating a high handle for that cup base, and could offer investors a new entry. ABCL stock slipped 1.5% to close at 13.36 on the stock ...The current average ABCL price target, as estimated by these analysts, is $27.75. The predictions for the future ABCL stock price range from a low of $18.00 to a high of …

According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.James O'Neil/DigitalVision via Getty Images. AbCellera Biologics ( NASDAQ: ABCL) to date has been quite a lousy investment. From the IPO high of $58.90, all the way down to the current price of ...Despite the fact that AbCellera Biologics Inc. (NASDAQ:ABCL) stock rose 20% last week, insiders who sold US$389m worth of stock in the previous 12 months are likely to be better off.View %COMPANY_NAME% ABC investment & stock information. Get the latest %COMPANY_NAME% ABC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.marketbeat.com - August 11 at 5:52 AM. AbCellera Biologics Board Member Makes $177K Stock Purchase. benzinga.com - August 10 at 1:28 PM. 19,432 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by Prime Capital Investment Advisors LLC. marketbeat.com - August 9 at 7:40 AM.Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating. Despite the fact that AbCellera Biologics Inc. (NASDAQ:ABCL) stock rose 20% last week, insiders who sold US$389m worth of stock in the previous 12 months are likely to be better off.

ABCL. The Nasdaq Stock Market. Indicate by check mark whether the registrant (1) ... The market price of our common stock could decline if one or more of these ...

Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Find the latest ABVC BioPharma, Inc. (ABVC) stock quote, history, news and other vital information to help you with your stock trading and investing.ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL.After dumping hundreds of millimetres of rain across New South Wales and Queensland, severe storms have moved south, where they are forecast to bring up to …Jan 5, 2023 · A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ... AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).Real time AbCellera Biologics (ABCL) stock price quote, stock graph, news & analysis.The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$4.83 Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

13 sept 2023 ... ABCL stock has a median price target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00, indicating potential for substantial ...AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).Based on 3 Wall Street analysts offering 12 month price targets for Workhorse Group in the last 3 months. The average price target is $2.83 with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 626.01% change from the last price of $0.39. Highest Price Target $4.00. Average Price Target $2.83.Instagram:https://instagram. t rowe price dividend growth fundhow much is 1979 one dollar coin worthnew residential investmenthummer 2017 Get in Touch. Micron Technology Inc., the largest US maker of computer memory semiconductors, suffered its worst stock decline in two months after warning …hace 4 días ... AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value on Thursday, November 30, with the stock price down by -0.31% to the previous ... best stocks under 20arrived home review 1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations. why is the dow dropping today AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners.